NNBXF Nanobiotix S.A.

Price Chart

Executive Summary

Nanobiotix priced an oversubscribed global offering of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raising approximately $98.6 million in gross proceeds. The offering, priced at $38.98 per ADS (a 14.92% discount to VWAP), will dilute existing shareholders by ~4.5% on a non-diluted basis. Proceeds are intended to fund pipeline development (primarily Nanoprimer and other platforms) and extend cash runway into 2029. The dilutive event is partially offset by strong demand (oversubscribed, with existing shareholders Qatar Holding and Invus participating) and a 90-day lock-up on insiders.

Actionable Insight

Key Facts

• Priced global offering of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants at $38.98 per ADS, a 14.92% discount to VWAP.
• Expected gross proceeds of approximately $98.6 million (~€85.0 million).
• Existing shareholders Qatar Holding LLC and Invus participated in the offering.
• Dilution of ~4.4% for a non-participating 1% shareholder on a non-diluted basis.
• Insiders and company subject to a 90-day lock-up.
• Proceeds: <10% to JNJ-1900 (NBTXR3), 50-60% to Nanoprimer and other platforms, 30-40% for general corporate purposes.
• Cash runway extended into 2029.
• Offering expected to close May 26, 2026.

Financial Impact

Gross proceeds of ~$98.6 million; dilution of ~4.4% for non-participating shareholders on a non-diluted basis.

Risk Factors

• Immediate dilution of ~4.4% for non-participating shareholders.
• Potential for further dilution if the 15% over-allotment option is exercised.
• Stock price may decline as new shares enter the market.
• Execution risk on pipeline spending plans.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status

Related Tickers